Pasar al contenido principal

BASES MOLECULARES DE LA PLASTICIDAD SINAPTICA ESTRIATAL EN LAS DISQUINESIAS Y EL TRASTORNO DE CONTROL DE IMPULSOS INDUCIDOS POR L-DOPA EN LA ENFERMEDAD DE PARKINSON

SAF2016-78207-R

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2016
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 11
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Oxidative stress, altered dopamine neurotransmission and increased susceptibility to nigrostriatal neurodegeneration in diabetic mice

  • Pérez-Taboada, Iara
  • Moratalla, Rosario
  • Vallejo, Mario
Póster presentado al 6th Symposium on Biomedical Research: Advances and Perspectives in Molecular Endocrinology "In Homage to Gabriella Morreale", celebrado en el Instituto de Investigaciones Biomédicas Alberto Sols (IIBM-CSIC) el 31 de mayo de 2019., Diabetes has been associated with increased risk of neurodegenerative diseases in a number of epidemiological studies, but the underlying mechanisms are unknown. In the case of Parkinson’s disease, this association has been confirmed in an increasing number of reports, although other fail to find a link. Here, using a mouse model of diabetes, we describe oxidative stress and neurotransmission alterations in the nigrostriatal system, and investigate whether diabetes increases the vulnerability of substantia nigra neurons to neurodegeneration. We used C57BL/6 mice rendered diabetic by streptozocin injections. Dopaminergic neuron and oxidative stress markers were determined by RT-qPCR or western blot. Striatal neurotransmitter and related metabolite levels were monitored by HPLC. Oxidative stress in the striatum was determined using commercial tests. [3H]-Dopamine uptake was assessed using striatal synaptosomes. After unilateral striatal injections of a sub-threshold dose of 6OHDA, motor performance was assessed using standard tests and neurodegenerative damage was histologically studied. The expression of genes involved in the regulation of the defense response against oxidative stress, including Nrf2, Keap1, Foxo1, catalase and SOD2 was altered in the substantia nigra of diabetic mice. SOD2 protein levels were unaffected, but catalase levels and activity were reduced. Oxidative stress was confirmed by elevated 4-HNE in the striatum. Diabetes resulted in decreased levels of dopamine and their metabolites in the striatum, without affecting those of noradrenaline or serotonine. Functional changes in neurotransmission were documented by reduced levels of the dopamine transporter DAT, the potassium channel Girk2, and the presynaptic vesicle markers VMAT2 and Syb2. However, dopamine reuptake was not significantly affected in diabetic animals. Finally, histological and motor performance tests revealed increased damage and motor impairment after 6OHDA injections in diabetic mice. Our data indicate that diabetic mice develop striatal oxidative stress and present altered striatal dopaminergic neurotransmission as well as increased vulnerability of nigrostriatal neurons to neurodegenerative damage, providing new insights into the pathophysiology of a possible relationship between diabetes and Parkinson’s disease., BFU2014-52149-R and BFU2017-89336-R to M.V.; SAF2016-78207-R and PCIN-2015-098 to R.M; FPU 14/04457 to I.P.T., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Changes in Dendritic Spine Density and Inhibitory Perisomatic Connectivity onto Medium Spiny Neurons in l-Dopa-Induced Dyskinesia

  • Gomez G
  • Escande, M.V.
  • Suarez L.M.
  • Rela, L.
  • Belforte J.E.
  • Moratalla, Rosario
  • Murer, Mario Gustavo
  • Gershanik, O.S.
  • Taravini, I.R.
Using bacterial artificial chromosome¿double transgenic mice expressing tdTomato in D1 receptor-medium spiny neurons (MSNs) and enhanced green fluorescent protein in D2 receptor-MSNs, we have studied changes in spine density and perisomatic GABAergic boutons density in MSNs of both the D1R and D2R pathways, in an experimental model of parkinsonism (mouse injected with 6-hydroxydopamine in the medial forebrain bundle), both in the parkinsonian and dyskinetic condition induced by l-DOPA treatment. To assess changes in perisomatic GABAergic connectivity onto MSNs, we measured the number of contacts originated from parvalbumin (PV)-containing striatal ¿fast-spiking¿ interneurons (FSIs), the major component of a feed-forward inhibition mechanism that regulates spike timing in MSNs, in both cell types as well as the number of vesicular GABA transporter (VGAT) contacts. Furthermore, we determined changes in PV-immunoreactive cell density by PV immunolabeling combined with Wisteria floribunda agglutinin (WFA) labeling to detect FSI in a PV-independent manner. We also explored the differential expression of striatal activity¿regulated cytoskeleton-associated protein (Arc) and c-Fos in both types of MSNs as a measure of neuronal activation. Our results confirm previous findings of major structural changes in dendritic spine density after nigrostriatal denervation, which are further modified in the dyskinetic condition. Moreover, the finding of differential modifications in perisomatic GABAergic connectivity and neuronal activation in MSNs suggests an attempt by the system to regain homeostasis after denervation and an imbalance between excitation and inhibition leading to the development of dyskinesia after exposure to l-DOPA., This work was supported by grants from the Argentine Agency for the Promotion of Science (PICT 2011-1758 and PICT 2015-3687), University of Buenos Aires (UBACyT 2014-2017 249), and Argentine National Research Council (CONICET, PIP 2013-0401) and by grants from the Spanish Ministries of Economía, Industria y Competitividad (SAF2016-78207-R) and PCIN-2015-098 and of Sanidad Servicios Sociales e Igualdad (ISCIII, CIBERNED CB06/05/0055, PNSD2016I033) and 172275 from Ramón Areces Foundation to RM. GG is a research fellow of the CONICET. LR, JEB, MGM, and IRET are members of the research career of CONICET.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Optostimulation of striatonigral terminals in substantia nigra induces dyskinesia that increases after L-DOPA in a mouse model of Parkinson's disease.

  • Keifman, Ettel
  • Ruiz de Diego, Irene
  • Pafundo, Diego Esteban
  • Paz, Rodrigo Manuel
  • Solís, O.
  • Murer, Mario Gustavo
  • Moratalla, Rosario
BACKGROUND AND PURPOSE: L-DOPA-induced dyskinesia (LID) remains a major complication of L-DOPA therapy in Parkinson's disease. LID is believed to result from inhibition of substantia nigra reticulata (SNr) neurons by GABAergic striatal projection neurons that become supersensitive to dopamine receptor stimulation after severe nigrostriatal degeneration. Here we asked if stimulation of direct medium spiny neuron (dMSN) GABAergic terminals at the SNr can produce a full dyskinetic state similar to that induced by L-DOPA. EXPERIMENTAL APPROACH: Adult C57BL6 mice were lesioned with 6-hydroxydopamine (6-OHDA) in the medial forebrain bundle. Channelrhodopsin was expressed in striatonigral terminals by ipsilateral striatal injection of adeno-associated viral particles under the CaMKII promoter. Optic fibres were implanted on the ipsilateral SNr. Optical stimulation was performed before and 24 h after three daily doses of L-DOPA at subthreshold and suprathreshold dyskinetic doses. We also examined the combined effect of light stimulation and an acute L-DOPA challenge. KEY RESULTS: Optostimulation of striatonigral terminals inhibited SNr neurons and induced all dyskinesia subtypes (optostimulation-induced dyskinesia; OID) in 6-OHDA animals, but not in sham-lesioned animals. Additionally, chronic L-DOPA administration sensitized the dyskinetic response to striatonigral terminal optostimulation, as OIDs were more severe 24 h after L-DOPA administration. Furthermore, L-DOPA combined with light stimulation did not result in higher dyskinesia scores than OID alone, suggesting that optostimulation has a masking effect on LID. CONCLUSION AND IMPLICATIONS: This work suggests that striatonigral inhibition of basal ganglia output (SNr) is a decisive mechanism mediating LID and identifies the SNr as a target for managing LID., This work was supported by grants from the Spanish Ministries of Economy and Competitiveness (SAF2016‐78207‐R and PCIN‐2015‐098) and Health, Social Services and Equality (PNSD 2016/033 and CIBERNED CB06/05/0055) and from the Fundación Ramón Areces (172275 and OTR02679). Funding was also provided by the EMHE “Enhancing Mobility between Latin American and Caribbean countries and Europe”—CSIC program, by ANPCYT (Agency for the Promotion of Science and Technology, Argentina), PICT 2013 1523 and 20153687, and by the University of Buenos Aires (UBACYT 2018). We thank Jesica Unger and Veronica Risso for their technical assistance.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Genetic Knockdown of mGluR5 in Striatal D1R-Containing Neurons Attenuates L-DOPA-Induced Dyskinesia in Aphakia Mice.

  • García-Montes, José Rubén
  • Solís, O.
  • Enríquez-Traba J
  • Ruiz-DeDiego, I.
  • Drucker-Colín R
  • Moratalla, Rosario
L-DOPA is the main pharmacological therapy for Parkinson's disease. However, long-term exposure to L-DOPA induces involuntary movements termed dyskinesia. Clinical trials show that dyskinesia is attenuated by metabotropic glutamate receptor type 5 (mGluR5) antagonists. Further, the onset of dyskinesia is delayed by nicotine and mGluR5 expression is lower in smokers than in non-smokers. However, the mechanisms by which mGluR5 modulates dyskinesia and how mGluR5 and nicotine interact have not been established. To address these issues, we studied the role of mGluR5 in D1R-containing neurons in dyskinesia and examined whether nicotine reduces dyskinesia via mGluR5. In the aphakia mouse model of Parkinson's disease, we selectively knocked down mGluR5 in D1R-containing neurons (aphakia-mGluR5KD-D1). We found that genetic downregulation of mGluR5 decreased dyskinesia in aphakia mice. Although chronic nicotine increased the therapeutic effect of L-DOPA in both aphakia and aphakia-mGluR5KD-D1 mice, it caused a robust reduction in dyskinesia only in aphakia, and not in aphakia-mGluR5KD-D1 mice. Downregulating mGluR5 or nicotine treatment after L-DOPA decreased ERK and histone 3 activation, and FosB expression. Combining nicotine and mGluR5 knockdown did not have an added antidyskinetic effect, indicating that the effect of nicotine might be mediated by downregulation of mGluR5 expression. Treatment of aphakia-mGluR5KD-D1 mice with a negative allosteric modulator did not further modify dyskinesia, suggesting that mGluR5 in non-D1R-containing neurons does not play a role in its development. In conclusion, this work suggests that mGluR5 antagonists reduce dyskinesia by mainly affecting D1R-containing neurons and that the effect of nicotine on dyskinetic signs in aphakia mice is likely via mGluR5., This work was supported by grants from the Spanish Ministerios de Economía y Competitividad and of Sanidad Política Social e Igualdad, ISCIII: SAF2016-78207-R, CIBERNED ref. CB06/05/0055, PNSD 2016/33, and PCIN 2015-098; and Foundation Ramon Areces and Secretaria de Ciencia Tecnología e Innovación de la Ciudad de Mexico (037-2016) to RM.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Hypomorphic Expression of Pitx3 Disrupts Circadian Clocks and Prevents Metabolic Entrainment of Energy Expenditure

  • Río Martín, Almudena Rosa del
  • Pérez-Taboada, Iara
  • Fernández-Pérez, Antonio
  • Moratalla, Rosario
  • Villa Polo, Pedro de la
  • Vallejo, Mario
© 2019 The Author(s)., Daily adaptation of metabolic activity to light-dark cycles to maintain homeostasis is controlled by hypothalamic nuclei receiving information from the retina and from nutritional inputs that vary according to feeding cycles. We show that selective hypomorphic expression of the transcription factor gene Pitx3 prevents light-dependent entrainment of the central pacemaker in the suprachiasmatic nucleus. This translates into altered behavioral and metabolic outputs affecting locomotor activity, feeding patterns, energy expenditure, and corticosterone secretion that correlate with dysfunctional expression of clock genes in the ventromedial hypothalamus, liver, and brown adipose tissue. Metabolic entrainment by time-restricted feeding restores clock function in the liver and brown adipose tissue but not in the ventromedial hypothalamus and, remarkably, fails to synchronize energy expenditure and locomotor and hormonal outputs. Thus, our study reveals a central role of the priming of the suprachiasmatic nucleus with retinal innervation in the hypothalamic regulation of cyclic metabolic homeostasis., This work was funded by the Spanish Ministry of Economy and Competitiveness (grants BFU2014-52149-R and BFU2017-89336-R to M.V. and SAF2016-78207-R to R.M.) and by the Instituto de Salud Carlos III, Spain (grants PI13-02098 and RETICs RD12/0034/0006 and RD16/0008/0020 to P.d.l.V.) and was partially supported by European FEDER funds. A.d.R.-M. was partially supported by CIBERNED. CIBERDEM and CIBERNED are initiatives of the Instituto de Salud Carlos III. I.P.-T. was supported by a fellowship from the Spanish Ministry of Education, Culture and Sports (FPU 14/04457)
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Differential Synaptic Remodeling by Dopamine in Direct and Indirect Striatal Projection Neurons in Pitx3 -/- Mice, a Genetic Model of Parkinson's Disease

  • Moratalla, Rosario
In toxin-based models of Parkinson's disease (PD), striatal projection neurons (SPNs) exhibit dendritic atrophy and spine loss concurrent with an increase in excitability. Chronic l-DOPA treatment that induces dyskinesia selectively restores spine density and excitability in indirect pathway SPNs (iSPNs), whereas spine loss and hyperexcitability persist in direct pathway SPNs (dSPNs). These alterations have only been characterized in toxin-based models of PD, raising the possibility that they are an artifact of exposure to the toxin, which may engage compensatory mechanisms independent of the PD-like pathology or due to the loss of dopaminergic afferents. To test all these, we studied the synaptic remodeling in Pitx3-/- or aphakia mice, a genetic model of PD, in which most of the dopamine neurons in the substantia nigra fail to fully differentiate and to innervate the striatum. We made 3D reconstructions of the dendritic arbor and measured excitability in identified SPNs located in dorsal striatum of BAC-Pitx3-/- mice treated with saline or l-DOPA. Both dSPNs and iSPNs from BAC-Pitx3-/- mice had shorter dendritic trees, lower spine density, and more action potentials than their counterparts from WT mice. Chronic l-DOPA treatment restored spine density and firing rate in iSPNs. By contrast, in dSPNs, spine loss and hyperexcitability persisted following l-DOPA treatment, which is similar to what happens in 6-OHDA WT mice. This indicates that dopamine-mediated synaptic remodeling and plasticity is independent of dopamine innervation during SPN development and that Pitx3-/- mice are a good model because they develop the same pathology described in the toxins-based models and in human postmortem studies of advanced PD.SIGNIFICANCE STATEMENT As the only genetic model of Parkinson's disease (PD) that develops dyskinesia, Pitx3-/- mice reproduce the behavioral effects seen in humans and are a good system for studying dopamine-induced synaptic remodeling. The studies we present here establish that the structural and functional synaptic plasticity that occur in striatal projection neurons in PD and in l-DOPA-induced dyskinesia are specifically due to modulation of the neurotransmitter dopamine and are not artifacts of the use of chemical toxins in PD models. In addition, our findings provide evidence that synaptic plasticity in the Pitx3-/- mouse is similar to that seen in toxin models despite its lack of dopaminergic innervation of the striatum during development. Pitx3-/- mice reproduced the alterations described in patients with advanced PD and in well accepted toxin-based models of PD and dyskinesia. These results further consolidate the fidelity of the Pitx3-/- mouse as a PD model in which to study the morphological and physiological remodeling of striatal projection neurons by administration of l-DOPA and other drugs., This work was supported by grants from the Spanish Ministries of Economía, Industria y Competitividad (SAF2016-78207-R and PCIN-2015-098) and of Sanidad Servicios Sociales e Igualdad, Instituto de Salud Carlos III (ISCIII), Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas [CIBERNED] (CB06/05/0055, PNSD2016I033), the Ramón Areces Foundation (172275), and from Secretaría de Ciencia, Tecnología e Innovacíon [SECITI] from Ciudad de Mexico (037/2016) to R.M., J.R.G.-M. received scholarships from Consejo Nacional de Ciencia y Tecnología and SECITI of Ciudad de Me ́xico. L.M.S., S.A., and R.M. were awarded the First Prize and SpecialPrize at the XV Archimedes University Competition from the Spanish Ministry of Educación Cultura y Deporte and ONCE Foundation.We thank Beatriz Pro and Emilia Rubio for technical assistance and Dr. J. DeFelipe fo rproviding the Lucifer yellow antibody.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Beneficial effects of the phytocannabinoid Δ9-THCV in L-DOPA-induced dyskinesia in Parkinson's disease

  • Espadas Villanueva, Isabel
  • Keifman, Ettel
  • Palomo-Garo, Cristina
  • Burgaz, S.
  • García, C.
  • Fernández-Ruiz, Javier
  • Moratalla, Rosario
The antioxidant and CB receptor agonist properties of Δ-tetrahydrocannabivarin (Δ-THCV) afforded neuroprotection in experimental Parkinson's disease (PD), whereas its CB receptor antagonist profile at doses lower than 5 mg/kg caused anti-hypokinetic effects. In the present study, we investigated the anti-dyskinetic potential of Δ-THCV (administered i.p. at 2 mg/kg for two weeks), which had not been investigated before. This objective was investigated after inducing dyskinesia by repeated administration of L-DOPA (i.p. at 10 mg/kg) in a genetic model of dopaminergic deficiency, Pitx3 mutant mice, which serves as a useful model for testing anti-dyskinetic agents. The daily treatment of these mice with L-DOPA for two weeks progressively increased the time spent in abnormal involuntary movements (AIMs) and elevated their horizontal and vertical activities (as measured in a computer-aided actimeter), signs that reflected the dyskinetic state of these mice. Interestingly, when combined with L-DOPA from the first injection, Δ-THCV delayed the appearance of all these signs and decreased their intensity, with a reduction in the levels of FosB protein and the histone pAcH3 (measured by immunohistochemistry), which had previously been found to be elevated in the basal ganglia in L-DOPA-induced dyskinesia. In addition to the anti-dyskinetic effects of Δ-THCV when administered at the onset of L-DOPA treatment, Δ-THCV was also effective in attenuating the intensity of dyskinesia when administered for three consecutive days once these signs were already present (two weeks after the onset of L-DOPA treatment). In summary, our data support the anti-dyskinetic potential of Δ-THCV, both to delay the occurrence and to attenuate the magnitude of dyskinetic signs. Although further studies are clearly required to determine the clinical significance of these data in humans, the results nevertheless situate Δ-THCV in a promising position for developing a cannabinoid-based therapy for patients with PD., This work was supported by grants from CIBERNED (CB06/05/0055 (RM), PI2018/01-3 (JF-R) and CB06/05/0089 (JF-R)), MINEICO (SAF2016-78207-R and PCIN-2015-098 (RM), and SAF2015-68580-C2-1-R to JF-R), Instituto de Salud Carlos III (PNSD2016I033) (RM), the Ramón Areces Foundation (172275) (RM), and GW Research Ltd., UK (JF-R). Funding was also provided by the EMHE “Enhancing Mobility between Latin American and Caribbean countries and Europe”- a CSIC program, to Ettel Keifman. Sonia Burgaz is a predoctoral fellow supported by the Complutense University-Predoctoral Programme. These agencies had no further role in study design, collection, analysis and interpretation of the data, in the writing of the report, or in the decision to submit the paper for publication.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Dopamine regulates spine density in striatal projection neurons in a concentration-dependent manner.

  • Alberquilla, Samuel
  • González-Granillo, Aldo
  • Martín, E.D.
  • Moratalla, Rosario
Dopaminergic afferents innervate spiny projection neurons (SPNs) in the striatum, maintaining basal gangliaactivity. The loss of striatal innervation is the hallmark of Parkinson's disease (PD), which is characterized bydopaminergic denervation. A lack of dopamine in the dorsal striatum induces plasticity changes in SPNs.However, PD-associated denervation is progressive, and how plasticity is modified in partially innervated areasis poorly understood. The most studied models of PD are based on the use of neurotoxins that induce an almostcomplete striatal denervation. To investigate the impact of partial dopamine (DA) innervation in striatal plas-ticity, we use a genetic model of PD, Aphakia (Ak) mice, whose striatum presents an increasing dorso-ventralgradient of dopamine innervation. We studied SPNs in three different areas (dorsal, middle and ventral, withlow, moderate and high innervation by tyrosine hydroxylase TH-positive axons, respectively) using fast scancyclic voltammetry, microiontophoresis, immunohistochemistry and patch clamp techniques. Our data show anincreasing dorso-ventral gradient of extracellular DA levels, overlapping with the gradient of TH innervation.Interestingly, spine loss in both direct (d-SPN) and indirect SPNs (i-SPN) decreases from dorsal to ventral in theparkinsonian striatum of Ak mice, following the decrease in DA levels. However, their dendritic trees and thenumber of nodes are only reduced in the poorly innervated dorsal areas and remain unaltered in moderate andhighly innervated areas. Thefiring rate of direct SPNs does not change in either moderate or highly innervatedareas, but increases in poorly innervated areas. In contrast, action potential frequency of indirect SPNs does notchange along the dorso-ventral innervation gradient. Ourfindings indicate that spine density in d-SPNs and i-SPNs varies in a dopamine concentration-dependent manner, indicating that both d- and i-SPN are similarlyinnervated by DA., This work was supported by grants from the Spanish Ministries of Economía, Industria y Competitividad (SAF2016-78207-R and PCIN-2015-098) and of Sanidad Servicios Sociales e Igualdad, Instituto de Salud Carlos III (ISCIII), Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas [CIBERNED] (CB06/05/0055, PNSD2016I033), the Ramón Areces Foundation (172275) to R.M. and BFU2017-88393-P from the Ministerio de Ciencia, Innovación y Universidades (MCIU), to E.D.M. We are very grateful to Dr. Oscar Solís for his critical comments on the manuscript. We would like to thank Dr. J. DeFelipe for providing the Lucifer yellow antibody.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Modeling Parkinson’s Disease With the Alpha-Synuclein Protein

  • Gómez-Benito, Mónica
  • Granado, Noelia
  • García-Sanz, Patricia
  • Michel, A.
  • Dumoulin, M.
  • Moratalla, Rosario
Alpha-synuclein (α-Syn) is a key protein involved in Parkinson's disease (PD) pathology. PD is characterized by the loss of dopaminergic neuronal cells in the substantia nigra pars compacta and the abnormal accumulation and aggregation of α-Syn in the form of Lewy bodies and Lewy neurites. More precisely, the aggregation of α-Syn is associated with the dysfunctionality and degeneration of neurons in PD. Moreover, mutations in the SNCA gene, which encodes α-Syn, cause familial forms of PD and are the basis of sporadic PD risk. Given the role of the α-Syn protein in the pathology of PD, animal models that reflect the dopaminergic neuronal loss and the widespread and progressive formation of α-Syn aggregates in different areas of the brain constitute a valuable tool. Indeed, animal models of PD are important for understanding the molecular mechanisms of the disease and might contribute to the development and validation of new therapies. In the absence of animal models that faithfully reproduce human PD, in recent years, numerous animal models of PD based on α-Syn have been generated. In this review, we summarize the main features of the α-Syn pre-formed fibrils (PFFs) model and recombinant adeno-associated virus vector (rAAV) mediated α-Syn overexpression models, providing a detailed comparative analysis of both models. Here, we discuss how each model has contributed to our understanding of PD pathology and the advantages and weakness of each of them. Significance: Here, we show that injection of α-Syn PFFs and overexpression of α-Syn mediated by rAAV lead to a different pattern of PD pathology in rodents. First, α-Syn PFFs models trigger the Lewy body-like inclusions formation in brain regions directly interconnected with the injection site, suggesting that there is an inter-neuronal transmission of the α-Syn pathology. In contrast, rAAV-mediated α-Syn overexpression in the brain limits the α-Syn aggregates within the transduced neurons. Second, phosphorylated α-Syn inclusions obtained with rAAV are predominantly nuclear with a punctate appearance that becomes diffuse along the neuronal fibers, whereas α-Syn PFFs models lead to the formation of cytoplasmic aggregates of phosphorylated α-Syn reminiscent of Lewy bodies and Lewy neurites., This work was supported by grants from the Spanish Ministries of Science and Innovation (SAF2016-78207-R) and of Health, Consumption and Social Welfare, Instituto de Salud Carlos III (ISCIII), Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas [CIBERNED] (CB06/05/00559 and PNSD2016I033) and from Ramón Areces Foundation (172275) and from Europan Union´s Horizon 2020, research and innovation program, AND-PD project, grant agreement n° 848002 to RM and from the ERA-Net Euronanomed II JTC2015-DiaSyn project through the Spanish Ministries of Innovation, Science and Universities (PCIN-2015-98) to RM and the Walloon Region (SPW, DG06, Belgium) to AM and MD (project N° n°1510352). MG-B was supported by a fellowship JAE-Intro 2019 from Consejo Superior de Investigaciones Científicas. The authors acknowledge support of the publication fee by the CSIC Open Access Publication Support Initiative through its Unit of Information Resources for Research (URICI).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Diabetes causes dysfunctional dopamine neurotransmission favoring nigrostriatal degeneration in mice

  • Pérez-Taboada, Iara
  • Alberquilla, Samuel
  • Martín, Eduardo D.
  • Anand, Rishi
  • Vietti-Michelina, Stefania
  • Tebeka, Nchimunya N.
  • Cantley, James
  • Cragg, Stephanie J.
  • Moratalla, Rosario
  • Vallejo, Mario
This article also appears in: Special Collection: COVID-19 Resources., [Background]: Numerous studies indicate an association between neurodegenerative and metabolic diseases. Although still a matter of debate, growing evidence from epidemiological and animal studies indicate that preexisting diabetes increases the risk to develop Parkinson's disease. However, the mechanisms of such an association are unknown., [Objectives]: We investigated whether diabetes alters striatal dopamine neurotransmission and assessed the vulnerability of nigrostriatal neurons to neurodegeneration., [Methods]: We used streptozotocin‐treated and genetically diabetic db/db mice. Expression of oxidative stress and nigrostriatal neuronal markers and levels of dopamine and its metabolites were monitored. Dopamine release and uptake were assessed using fast‐scan cyclic voltammetry. 6‐Hydroxydopamine was unilaterally injected into the striatum using stereotaxic surgery. Motor performance was scored using specific tests., [Results]: Diabetes resulted in oxidative stress and decreased levels of dopamine and its metabolites in the striatum. Levels of proteins regulating dopamine release and uptake, including the dopamine transporter, the Girk2 potassium channel, the vesicular monoamine transporter 2, and the presynaptic vesicle protein synaptobrevin‐2, were decreased in diabetic mice. Electrically evoked levels of extracellular dopamine in the striatum were enhanced, and altered dopamine uptake was observed. Striatal microinjections of a subthreshold dose of the neurotoxin 6‐hydroxydopamine in diabetic mice, insufficient to cause motor alterations in nondiabetic animals, resulted in motor impairment, higher loss of striatal dopaminergic axons, and decreased neuronal cell bodies in the substantia nigra., [Conclusions]: Our results indicate that diabetes promotes striatal oxidative stress, alters dopamine neurotransmission, and increases vulnerability to neurodegenerative damage leading to motor impairment., Funded by the Spanish Ministries of Economy and Competitiveness (grants BFU2014‐52149‐R and BFU2017‐89336‐R to M.V., SAF2016‐78207‐R and PCIN‐2015‐098 to R.M., and BFU2017‐88393‐P to E.D.M.) and of Health, Social Services and Equality (PNSD‐2016I033 to R.M.) and by the Ramón Areces Foundation (ref. 172275 to R.M.). Supported by Medical Research Council UK iCASE award (to S.J.C., R.A.), a Biotechnology and Biological Sciences Research Council UK studentship (to S.V.M.), and Parkinson's UK (J‐1403 to S.J.C.). Partially supported by FEDER funds. CIBERDEM and CIBERNED are initiatives of the Instituto de Salud Carlos III. I.P.T. was supported by a fellowship from the Spanish Ministry of Education, Culture and Sports (FPU 14/04457)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Behavioral sensitization and cellular responses to psychostimulants are reduced in D2R knockout mice.

  • Solís, O.
  • García-Sanz, Patricia
  • Martín, A. B.
  • Granado, Noelia
  • Sanz-Magro, Adrián
  • Podlesniy, Petar
  • Trullas, Ramón
  • Murer, Mario Gustavo
  • Maldonado, Rafael
  • Moratalla, Rosario
Repeated cocaine exposure causes long-lasting neuroadaptations that involve alterations in cellular signaling and gene expression mediated by dopamine in different brain regions, such as the striatum. Previous studies have pointed out to the dopamine D1 receptor as one major player in psychostimulants-induced behavioral, cellular, and molecular changes. However, the role of other dopamine receptors has not been fully characterized. Here we used dopamine D2 receptor knockout (D2−/−) mice to explore the role of D2 receptor (D2R) in behavioral sensitization and its associated gene expression after acute and chronic cocaine and amphetamine administration. We also studied the impact of D2R elimination in D1R-mediated responses. We found that cocaine- and amphetamine-induced behavioral sensitization is deficient in D2−/− mice. The expression of dynorphin, primarily regulated by D1R and a marker of direct-pathway striatal neurons, is attenuated in naïve- and in cocaine- or amphetamine-treated D2−/− mice. Moreover, c-Fos expression observed in D2−/− mice was reduced in acutely but not in chronically treated animals. Interestingly, inactivation of D2R increased c-Fos expression in neurons of the striatopallidal pathway. Finally, elimination of D2R blunted the locomotor and striatal c-Fos response to the full D1 agonist SKF81297. In conclusion, D2R is critical for the development of behavioral sensitization and the associated gene expression, after cocaine administration, and it is required for the locomotor responses promoted by D1R activation., This work was supported by grants from the Spanish Ministries of Innovation, Science and Universities (SAF2016-78207-R and PCIN2015-098 to R. Moratalla, SAF2017-84060-R-AEI/FEDER-UE to R. Maldonado, and SAF2017-89791-R to P. Podlesniy and R. Trullas) and Health, Social Services and Equality (PNSD 2016/033 and CIBERNED CB06/05/0055 to R. Moratalla and RETICS/RTA, RD16/0017 to R.Maldonado.) and from the Ramón Areces Foundation (172275 and OTR02679) to R. Moratalla and ANPCYT (Agency for the Promotion of Science and Technology, Argentina), PICT 2013 1523 and 2015 3687 and by the University of Buenos Aires (UBACYT 2018) to M.G.M. and the Catalan Government (AGAUR, #ICREA Acadèmia-2015 and #2017-SGR-669) to R. Maldonado.